Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.

Indirect comparison Based on the DIC values in indirect comparisons (Figure 4 ), the fixed-effects model had better model fit than random-effects models, with relatively lower DIC values for the two outcomes, suggesting that the interstudy heterogeneity might not be significant.

also in 673 other papers